Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03026062
Title Durvalumab and Tremelimumab in Combo Versus Sequential
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

peritoneum cancer

fallopian tube cancer

ovarian cancer

Therapies

Tremelimumab

Durvalumab + Tremelimumab

Durvalumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.